Tema Oncology ETF Rating $25.40 -0.76 (-2.91%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$25.35 -0.05 (-0.20%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.80Holdings in CANC have an aggregate rating of Moderate Buy based on 592 analyst ratings issued in the past year covering 46 companies (87.4% of the portfolio).CANC Aggregate Price Target$25.40High Prediction$25.40Average Prediction$25.40Low Prediction$25.40Holdings in CANC have an aggregate price target of $25.40 and a range of $25.40 to $25.40 covering 46 companies (87.4% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy19 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 46 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.28%RVMDRevolution Medicines$40.59-1.3%4.4199 of 5 stars3.00$67.08 65.3%12Positive News5.16%LLYEli Lilly and Company$818.56+0.8%4.8034 of 5 stars2.76$1,011.37 23.6%21Trending NewsAnalyst Revision5.10%RHHBYRoche$41.32-1.5%N/A2.5774.16%BBIOBridgeBio Pharma$39.78+0.3%4.606 of 5 stars2.92$57.36 44.2%12Insider TradeAnalyst Revision4.02%EXELExelixis$41.59-0.5%4.3793 of 5 stars2.47$39.76 -4.4%19Analyst Forecast3.97%GMABGenmab A/S$22.82-1.2%3.8361 of 5 stars2.69$39.17 71.6%13Analyst Downgrade3.86%MRUSMerus$54.61-1.4%3.0717 of 5 stars3.13$85.83 57.2%153.59%BMYBristol-Myers Squibb$49.71-1.9%4.8409 of 5 stars2.32$58.00 16.7%22Analyst Revision3.37%NUVLNuvalent$78.24+0.4%2.3271 of 5 stars2.90$115.50 47.6%103.31%AMGNAmgen$295.22-0.7%4.4609 of 5 stars2.38$309.22 4.7%24Positive NewsAnalyst Revision3.15%SMMTSummit Therapeutics$19.78-1.9%3.0563 of 5 stars2.77$35.09 77.4%13Analyst UpgradeAnalyst RevisionGap Up3.14%ZLABZai Lab$41.00-4.7%1.2747 of 5 stars2.75$47.37 15.5%4Analyst RevisionGap Down3.01%ACLXArcellx$66.00-0.8%2.621 of 5 stars3.07$111.33 68.7%14Insider TradeAnalyst RevisionGap Down2.85%LEGNLegend Biotech$36.83-2.8%3.0653 of 5 stars2.91$76.20 106.9%11Short Interest ↑Analyst RevisionGap Up2.71%ONCBeigene$269.63-2.5%1.3262 of 5 stars3.00$319.00 18.3%6Trending NewsInsider TradeGap Down2.50%MRKMerck & Co., Inc.$81.68-0.2%4.9964 of 5 stars2.43$109.19 33.7%21Positive NewsAnalyst Revision2.10%IDYAIDEAYA Biosciences$22.18-0.4%3.9444 of 5 stars2.93$54.27 144.7%14Analyst RevisionGap Down1.82%ABBVAbbVie$190.67-0.9%4.9006 of 5 stars2.81$211.29 10.8%27Trending NewsAnalyst ForecastAnalyst Revision1.75%JANXJanux Therapeutics$24.90-2.6%2.3737 of 5 stars3.09$95.25 282.5%11Positive NewsAnalyst Revision1.69%CGONCG Oncology$25.86-2.4%2.4622 of 5 stars3.00$58.22 125.1%11Positive NewsAnalyst RevisionGap Down1.47%IMNMImmunome$9.20-6.0%1.6388 of 5 stars3.00$23.33 153.6%6News CoveragePositive NewsGap Down1.43%ARGXargenx$577.89-1.5%3.488 of 5 stars3.05$709.18 22.7%22Analyst Forecast1.38%NRIXNurix Therapeutics$11.93-0.3%2.2407 of 5 stars2.83$30.18 152.9%18Gap Down1.31%REGNRegeneron Pharmaceuticals$529.24+1.4%4.8811 of 5 stars2.85$836.48 58.1%26Positive NewsAnalyst Revision1.29%SNDXSyndax Pharmaceuticals$10.25-3.9%3.054 of 5 stars2.91$35.91 250.3%11News CoveragePositive News1.17%GILDGilead Sciences$109.98-1.8%4.853 of 5 stars2.78$110.55 0.5%27Trending NewsOptions VolumeAnalyst Revision1.16%COGTCogent Biosciences$7.08-1.9%2.3081 of 5 stars2.75$14.57 105.8%8Positive NewsGap Down1.06%IMCRImmunocore$34.68-2.7%3.0509 of 5 stars2.55$58.89 69.8%11Positive NewsAnalyst UpgradeAnalyst Revision1.01%DAWNDay One Biopharmaceuticals$6.67-0.3%1.6084 of 5 stars3.13$30.57 358.3%8Positive News0.94%ELVNEnliven Therapeutics$21.91+11.4%2.5058 of 5 stars3.00$37.25 70.0%4News CoverageInsider TradeGap DownHigh Trading Volume0.90%ZYMEZymeworks$12.67-3.3%1.8681 of 5 stars2.90$21.00 65.7%10Positive NewsGap Down0.80%RCUSArcus Biosciences$9.25-1.1%2.3041 of 5 stars2.90$24.13 160.8%10Options VolumeAnalyst RevisionGap Up0.76%GHGuardant Health$49.29+0.6%3.734 of 5 stars3.00$53.76 9.1%21Analyst ForecastGap Down0.73%ARVNArvinas$7.39-2.4%3.8831 of 5 stars2.55$20.29 174.6%22Analyst RevisionGap Down0.62%AAPGAscentage Pharma Group International$31.51-1.6%N/A3.0010.61%SDGRSchrödinger$21.43-6.1%2.464 of 5 stars3.00$32.80 53.1%6Gap Down0.57%ILMNIllumina$86.93-1.4%4.8769 of 5 stars2.47$126.94 46.0%19Positive NewsAnalyst ForecastOptions Volume0.55%INCYIncyte$67.75-2.1%4.514 of 5 stars2.17$72.53 7.1%18Positive News0.55%REPLReplimune Group$9.78-1.1%4.5225 of 5 stars3.14$20.83 113.0%7Positive NewsGap Down0.51%CGEMCullinan Therapeutics$8.61-3.8%1.6936 of 5 stars3.00$30.00 248.4%5Analyst Forecast0.45%RLAYRelay Therapeutics$3.22-6.7%2.1788 of 5 stars2.83$17.67 448.7%12Gap Down0.37%AUTLAutolus Therapeutics$2.12-1.4%2.5645 of 5 stars3.00$9.32 339.6%5News CoveragePositive NewsAnalyst ForecastGap Up0.36%ANABAnaptysBio$23.32-0.4%1.7718 of 5 stars2.80$42.38 81.7%100.32%LNTHLantheus$77.83-2.9%4.4656 of 5 stars3.00$132.67 70.5%6Positive News0.29%CELCCelcuity$12.11-3.6%1.9153 of 5 stars3.17$30.80 154.3%6Positive News0.27%MREOMereo BioPharma Group$2.76-0.7%1.7008 of 5 stars3.17$7.67 177.8%6Positive NewsAnalyst Revision This page (NASDAQ:CANC) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CANC Stock Free CANC Stock Alerts